Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis
Status:
Recruiting
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well administering ruxolitinib before, during, and after
allogeneic hematopoietic stem cell transplantation works in preventing graft versus host
disease and improving transplant outcomes in patients with primary and secondary
myelofibrosis. Donor hematopoietic stem cell transplantation (HSCT) is currently the only
treatment with proven curative potential for myelofibrosis, however, myelofibrosis patients
have a high risk for developing graft versus host disease post-transplant. Graft versus host
disease is a condition where the transplanted cells from a donor can attack the body's normal
cells. Ruxolitinib, a janus-associated kinase (JAK) inhibitor, is known to decrease
inflammatory signals, which may reduce spleen size and decrease symptoms such as night sweats
and weight loss. Administering ruxolitinib before, during, and after transplant may decrease
the incidence and severity of graft versus host disease, increase survival, and improve
quality of life in patients with primary and secondary myelofibrosis.